AC
PCSA icon

Armistice Capital’s Processa Pharmaceuticals PCSA Stock Holding History

Armistice Capital’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,240
Closed -$20.7K – 253
2025
Q1 		$20.7K Buy
+2,240
New +$33.7K ﹤0.01% 217

Other funds holding PCSA

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Armistice Capital's PCSA Position: Q2 2025 in Review

Armistice Capital sold out of Processa Pharmaceuticals (PCSA) in Q2 2025, closing a stake of 2,240 shares — an estimated $20.7K sold.

Armistice Capital first reported a position in PCSA in Q1 2025 and held it in 1 quarter. The position peaked at $20.7K in Q1 2025. 11 funds tracked by Wall St. Rank hold PCSA as of Q2 2025.

  • Armistice Capital reported no remaining Processa Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Armistice Capital sold 2,240 Processa Pharmaceuticals shares in Q2 2025, an estimated $20.7K.
  • Armistice Capital first reported a position in Processa Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Armistice Capital's Processa Pharmaceuticals position peaked at $20.7K in Q1 2025.
  • 11 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q2 2025.

Based on Armistice Capital's 13F filing for Q2 2025, filed 14 Aug 2025.